Global Health Investment Corporation

We see enormous opportunity in historically overlooked market segments, and we leverage our unique expertise to translate these opportunities into social and financial returns for our investors. Adjuvant’s investment model is heavily influenced by global trends such as climate change, the empowerment of women and girls, urbanization, antimicrobial resistance, and globalization. These trends guide us toward looming public health threats and the high impact innovations that will address them. Built to Improve Health, for Everyone Our mission is simple: invest in the most promising public health technologies and ensure they are made accessible to those who need them most. We invest in innovative technologies to address high-burden and neglected infectious diseases, maternal and child health, and reproductive and sexual health. Within the infectious disease category, we focus on the "big three" (HIV/AIDS, tuberculosis, malaria), tropical diseases like schistosomiasis and onchocerciasis, pandemic threats such as Middle East Respiratory Syndrome (MERS) and Lassa fever, and anti-microbial resistance (AMR). The majority of our investment activity is built upon commercializing technologies that have demonstrated safety and efficacy in humans, with the goal of accelerating the global availability of the most impactful medical innovations. Investing in a Changing World Healthcare spending in emerging economies is one of the fastest growing sectors in the world. Global economic growth is moving billions of people into the middle class, while the call for universal health equity is driving more resources than ever to healthcare for low-income populations. Despite these trends, life sciences investment in this large and growing segment is remarkably low. Our unique focus targets innovations poised to deliver unprecedented health outcomes in underserved markets with the goal of generating truly differentiated "double-bottom-line" returns for our investors. A Global Network of Investors Working to Build a Healthier Future Adjuvant is backed by leading strategic investors and alternative asset managers who understand the global public health landscape, providing invaluable domain expertise and support on top of their capital commitments.

At StartUp Health, we are impact-driven entrepreneurs and investors building a global army of thousands of Health Transformers collaborating to achieve health moonshots --- from ending cancer and curing disease, like diabetes and Alzheimer’s, to delivering quality care to everyone in the world regardless of location or income. We believe that investing in and supporting a diversified global portfolio of health moonshot companies is the key to improving the health and wellbeing of humanity, while also generating healthy financial returns for investors. Since 2012, we’ve made more than 400 investments in companies across 27 countries, and currently have a portfolio of 260+ active companies. We have a flexible, work-from-anywhere policy as our team is fully remote, with team members in NYC, San Francisco, Los Angeles, Baltimore, and Philadelphia. We are open to candidates across the U.S. Benefits include health insurance and long-term disability coverage, 401k with employer matching, employee stock options, and generous time off policy including paid holidays.

Address the critical bottlenecks in both established and emerging markets that limit access and affordability to novel cancer solutions. Inculcate the tenets of ESG (Environmental, Social and Governance) based investing and measure the progress and impact of our portfolio using the following metrics: E: The ability to optimize differential drug and device pricing based on geography and expand access to promising products early in their lifecycle S: Ability to boost R&D productivity through operational optimization and process transformation G: Promote ethical conduct of business and collaboration while ensuring inclusion & diversity What We DoInvest in US and EU based cancer start-ups who are keen to explore emerging markets or engage in collaborative R&D. Streamline the product-market fit and ensure access to supportive infrastructure and resources. Facilitate their collaborative R&D/commercialization strategy in geographies of interest. How We Do It Accelerate the path to successful commercialization for US and EU based start-ups developing the next generation of oncology solutions by: Reducing costs through infrastructure consolidation and collaborative expertise Expanded access to capital Facilitating rapid market penetration and commercial scaling​

Cigna Ventures is the strategic venture fund of Cigna Corporation, a leading global health service company with more than 190 million customer relationships in more than 30 countries. We work closely with founders to accelerate the growth of their business by providing access to the right people and resources at the right time and enabling differentiated partnership opportunities with one of the largest health service companies in the world.

Rebel One is an early stage fund and global investor network accelerating rebel founders for a better world. We aim to democratize access to investing while solving the world’s most systemic problems aligned with our zero goals - zero pollution, zero poverty and zero disease. Our goal is to accelerate startups by building the world's largest community of angels investing in founders working to solve some of the world's greatest challenges.

Global Health X (GHX) is a Healthcare and Life Sciences Venture studio, accelerator and fund, serving as the Innovation and R&D arm of the Global University Foundation. Vision To nurture innovation at the intersection healthcare, life sciences and technology to make care accessible and affordable across the globe. Mission To create the largest healthcare and life sciences innovation hub by 2030, fostering collaboration and driving breakthroughs to improve patient outcomes. In addition to industry partners and service providers, we have built our ecosystem in Hyderabad to include a network of premier institutions like the Indian Institute of Technology (IIT), International Institute of Information Technology (IIIT), Centre for Cellular and Molecular Biology (CCMB) and others to create synergies for exponential advancements in Healthcare and Life Sciences innovation. Culture We’ve built our culture brick by brick and it forms the core of how we do what we do Agility and Experimentation: Foster a mindset that embraces rapid prototyping and iteration, allowing teams to quickly test and refine their solutions. Collaboration-Driven Innovation: Encourage cross-disciplinary teams to freely share knowledge and ideas, leading to creative and effective solutions. Mission-Focused Impact: Instil a shared purpose that emphasises improving patient outcomes and advancing scientific knowledge, driving teams to remain committed to meaningful projects.